Reports Q2 revenue $400,000. “ZEVASKYN’s launch is demonstrating positive early momentum,” said Vish Seshadri, Chief Executive Officer of Abeona. “The first ZEVASKYN patient treatment is on track for the third quarter of 2025 with multiple additional patients identified and advancing through the process to initiate treatment. The enthusiasm from the RDEB community and clinicians, alongside our substantial progress with payer coverage, affirms ZEVASKYN’s crucial role in transforming patient care.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- AscellaHealth highlights value of HUB partnership with Abeona Therapeutics
- Abeona Therapeutics Amends Loan Agreement with Avenue
- Abeona Therapeutics’ Gene Therapy Trial for MPS IIIA: A Promising Update
- Abeona announces ZEVASKYN available at new Qualified Treatment Center